EC Number   |
Application |
Reference |
|---|
   3.1.4.11 | drug development |
PLCgamma1 inhibitors may have potential therapeutic applications for the clinical treatment of tumor metastasis |
691606 |
| 3.1.4.11 | food industry |
the enzyme is used in industrial soybean oil degumming |
749707 |
| 3.1.4.11 | medicine |
increased expression of R257H mutant PLC delta1 in patients with coronary spastic angina, enhanced PLC delta1 activity, but not beta or gamma, in patients suffering from essential hypertension, PLC delta2 plays a role in neoplastic evolution and could be a predictive marker of cancer transformation |
649088 |
| 3.1.4.11 | medicine |
PLC-beta2 may constitute a molecular marker of breast tumor cells able to monitor the progression to invasive cancers and a target for novel therapeutic breast cancer strategies |
679067 |
| 3.1.4.11 | medicine |
PLC-gamma1 may permit the progression of some tumors |
653442 |
| 3.1.4.11 | medicine |
the leptospiral enzyme is a biomarker candidate for the serodiagnosis and pathogenesis of leptospirosis |
-, 751530 |
| 3.1.4.11 | pharmacology |
showing that pharmacological inhibition of PLC enhances intestinal Ca2+ transport. This raises the possibility that pharmacological tools targeting PLC can be used to enhance intestinal Ca2+ absorption. Given the prevalence of osteoporosis, which generally comes with negative Ca2+ balance, PLC can be a clinically relevant pharmacological target in the future |
694268 |
